PARACETAMOL IV MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Global paracetamol IV market is estimated to be valued at USD Mn 838.1 Mn in 2024 and is expected to reach USD Mn 1,054.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 3.3% from 2024 to 2031. Paracetamol, also known as acetaminophen, is among the most commonly used over-the-counter pain reliever and fever reducer. It is primarily used for treating headaches, muscle aches, backaches, toothaches, colds, and fevers. The intravenous route enables faster absorption of paracetamol into the bloodstream compared to the oral route. This makes the intravenous formulation a suitable option for patients who have difficulty in swallowing tablets or are experiencing severe pain. Rising cases of chronic diseases such as cancer, where pain management is crucial, can boost the demand for paracetamol IV solutions. Furthermore, rapid approval of new formulations and growing focus on pain management can present lucrative opportunities for global paracetamol IV market players over the forecast period.

Market Dynamics

Global paracetamol IV market growth is primarily driven by rising geriatric population worldwide who are more susceptible to chronic illnesses and injuries requiring pain management. According to the data published by the WHO, on October 1, 2024, the number of people aged 65 years or older is projected to increase from an estimated 524 million in 2010 to nearly 1.5 billion in 2050. Growing incidence of painful conditions like osteoporosis and arthritis in the elderly population boosts the need for potent intravenous painkillers. However, market growth can be hampered by certain challenges such as availability of alternative drugs and risk of adverse effects associated with prolonged usage of paracetamol IV. Ongoing medical advances in cancer research leads to the discovery of more effective therapies. This can boost demand for intravenous analgesics like paracetamol for managing chemotherapy-induced pain. Moreover, increasing focus of pharmaceutical companies on developing novel drug formulations can open new avenues for the paracetamol IV market.

Key features of the study

- This report provides in-depth analysis of the global paracetamol IV market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year

- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

- It profiles key players in the global paracetamol IV market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies

- Key companies covered as a part of this study include Johnson & Johnson, Fresenius Kabi AG, Baxter International Inc., Pfizer Inc., B. Braun Melsungen AG, Hikma Pharmaceuticals PLC, Amgen Inc., Sandoz (a Novartis division), Teva Pharmaceutical Industries Ltd., Mylan N.V., Eton Pharmaceuticals, Inc., Aurobindo Pharma Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., and Mallinckrodt Pharmaceuticals

- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

- Global paracetamol IV market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global paracetamol IV market

Market Segmentation

•  Type Insights (Revenue, USD Mn, 2019 - 2031)
• • Single Dose
  • Multi-Dose
•  Application Insights (Revenue, USD Mn, 2019 - 2031)
• • Pain Management
  • Fever Reduction
•  End User Insights (Revenue, USD Mn, 2019 - 2031)
• • Hospitals
  • Clinics
  • Homecare Settings
  • Others
• Regional Insights (Revenue, USD Mn, 2019 - 2031)
• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Johnson & Johnson
  • Fresenius Kabi AG
  • Baxter International Inc.
  • Pfizer Inc.
  • B. Braun Melsungen AG
  • Hikma Pharmaceuticals PLC
  • Amgen Inc.
  • Sandoz (a Novartis division)
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Eton Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Apotex Inc.
  • Mallinckrodt Pharmaceuticals